
Promising results for an FGFR 1–3 inhibitor in molecularly altered tumours
CPL304110 shows acceptable toxicity and early signs of activity in heavily pre-treated patients with advanced solid malignancies

New tools and methods are discussed for optimising investigation of precision therapeutics
Results of extensive genomic profiling and a Time-to-Event Continual Reassessment Method show some promise in investigating new treatments and targets in early-phase trials, despite not being ready for routine research

NGS – a weapon in molecular pathology?
Next generation sequencing has revolutionised cancer management, but has also raised some issues that have yet to be addressed

Early phase cancer research – ready for a change?
New recommendations of the MDICT Taskforce highlight the need to rethink how research studies are conducted and of multi-stakeholder collaboration

Ovarian cancer: updated phase III data provide reassurance for the use of PARPi as maintenance therapy
Sustained benefit of PARPi treatment may help to put the recent concerns on how and when to use these agents in women into context

Is ATR inhibition a potential new treatment for rare gynaecological cancers?
Ceralasertib, alone or in combination with PARP inhibition, showed signs of clinical efficacy in patients with relapsed ovarian and endometrial clear cell carcinomas (CCC), for whom effective treatment options are currently lacking

Is overall survival the right endpoint for PARPi trials in ovarian cancer?
Unfavourable overall survival data for PARP inhibitors in certain ovarian cancers prompts calls for caution in interpretation of the analyses and stimulates the search for surrogate measures of clinical benefit

HPV vaccination uptake reflects our efforts as one oncology community
Cervical cancer is a preventable disease so, although research advances are increasing treatment opportunities for all women diagnosed at any stage, we must stop it before it hits.